Letter: risk of inflammatory bowel disease is related to alcohol consumption as well as ACEIs and ARBs-authors' reply

被引：0
|
作者：
Khalili, Hamed [1 ]
Casey, Kevin [2 ]
机构：
[1] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Clin & Translat Epidemiol Unit, Boston, MA 02114 USA
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2022年 / 55卷 / 07期
关键词：
D O I：
10.1111/apt.16842
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：884 / 884
页数：1
相关论文
共 50 条
  • [31] Editorial: anxiety and depression in inflammatory bowel disease - authors' reply
    Stapersma, Luuk
    van den Brink, Gertrude
    Szigethy, Eva M.
    Escher, Johanna C.
    Utens, Elisabeth M. W. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (06) : 687 - 688
  • [32] The changing epidemiology of paediatric inflammatory bowel disease: authors' reply
    Chouraki, V.
    Turck, D.
    Colombel, J. -F.
    Gower-Rousseau, C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (12) : 1381 - 1382
  • [33] Editorial: migration studies to determine risk and cause of inflammatory bowel disease-authors' reply
    Damas, Oriana M.
    Schwartz, Seth J.
    Abreu, Maria T.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (04) : 467 - 467
  • [34] Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease-Authors' reply
    Qiu, X. Y.
    Lu, M. J.
    Zhang, H. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (05) : 690 - 691
  • [35] Depression in inflammatory bowel disease: risk factor, prodrome or extraintestinal manifestation? Reply from authors
    Frolkis, Alexandra D.
    Vallerand, Isabelle A.
    Patten, Scott B.
    Kaplan, Gilaad G.
    GUT, 2020, 69 (03) : 611 - 612
  • [36] Letter: faecal volatile organic metabolites, promising biomarkers in inflammatory bowel disease and Letter: faecal volatile organic metabolites as novel diagnostic biomarkers in inflammatory bowel disease. Authors' reply
    Ahmed, I.
    Greenwood, R.
    Costello, B.
    Ratcliffe, N.
    Probert, C.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 43 (11) : 1241 - 1242
  • [37] Alcohol consumption and risk of inflammatory bowel disease among three prospective US cohorts
    Casey, Kevin
    Lopes, Emily W.
    Niccum, Blake
    Burke, Kristin
    Ananthakrishnan, Ashwin N.
    Lochhead, Paul
    Richter, James M.
    Chan, Andrew T.
    Khalili, Hamed
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (02) : 225 - 233
  • [38] Letter: fighting the battle but losing the war-inflammatory bowel disease and venous thromboembolism. Authors' reply
    Lee, Kate E.
    Faye, Adam S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (09) : 1427 - 1428
  • [39] Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease - authors' reply
    Chaparro, M.
    Gisbert, J. P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (07) : 940 - 941
  • [40] Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply
    Mahadevan, U.
    Vermeire, S.
    Lasch, K.
    Abhyankar, B.
    Bhayat, F.
    Blake, A.
    Dubinsky, M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 48 (03) : 388 - 389
12345